z-logo
Premium
Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars
Author(s) -
Guadanhim Lilia R. S.,
Gonçalves Rubens G.,
Bagatin Ediléia
Publication year - 2016
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.13317
Subject(s) - medicine , isotretinoin , acne , dermatology , keloid , hypertrophic scars , scars , acne scars , surgery
Background Acne vulgaris is a chronic inflammatory disease characterized by non‐inflammatory and inflammatory lesions that can cause scarring. Oral isotretinoin is the current recommended treatment for moderate and severe cases; however, there are reports of possible influences on the healing process of the skin, leading to an increase in the risk for hypertrophic scars and keloids. This hypothesis, although unproven, represents a contraindication to the treatment of acne scars during the 6–12 months after the cessation of isotretinoin. Objectives The aim of this study was to investigate the prevalences of hypertrophic scars and keloids in acne patients treated with oral isotretinoin. Methods Three data collection strategies were used: (i) clinical examination of patients with acne vulgaris, exposed or unexposed to oral isotretinoin, focusing on the occurrence of hypertrophic scars and/or keloids; (ii) telephone interviews of patients using oral isotretinoin to treat acne vulgaris on the occurrence or worsening of keloids; and (iii) clinical examination of patients with previous use of oral isotretinoin followed at a specific keloid treatment clinic. Results The resulting data showed no differences in wound healing. Conclusions These findings may indicate that the occurrence of hypertrophic scars or keloids in patients using oral isotretinoin is an undesirable event arising from an individual response and may be related to inflammatory acne evolution.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here